Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation
Recruitment status was Recruiting
The purpose of this study is to compare the efficacy of two controlled ovarian stimulation protocols, the GnRH agonist protocol, widely known as the "long" protocol, and the flexible GnRH antagonist protocol, in terms of pregnancy rates and embryological data, in infertile patients receiving IVF treatment.
Drug: Arvekap 0.1 mg (Triptorelin, Ipsen, France)
Drug: Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Randomized Controlled Trial Comparing the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation in Normal Responders|
- Ongoing pregnancy per embryo transfer
- Biochemical pregnancy per embryo transfer
- Clinical pregnancy per embryo transfer
- Embryological data
|Study Start Date:||September 2005|
|Estimated Study Completion Date:||June 2007|
The formulation of controlled ovarian stimulation protocols is one of the primary reasons for the successful development of IVF. The "long" GnRH agonist protocol, also known as the gold standard, has been widely used with considerable success. More recently, on the other hand, GnRH antagonist provide a new promising approach for endogenous gonadotrophin suppression by blocking the GnRH receptor. There is conflicting data in the literature regarding the relative merits of the two ovarian stimulation protocols.
COMPARISON: Pregnancy rates and embryological data will by assessed in IVF patients treated with either the "long" GnRH agonist (Arvekap) or the flexible GnRH antagonist (Ganirelix) protocol.
|Contact: Tryfon Lainas, PhDfirstname.lastname@example.org|
|Athens, Greece, 11528|
|Contact: Tryfon Lainas, PhD 00302107236333 email@example.com|
|Principal Investigator:||Tryfon Lainas, PhD||Eugonia|